✦ LIBER ✦

Conformed radiotherapy and chemotherapy with cisplatin/tegafur in cervix cancer

✍ Scribed by Caeiro, M.; Huidobro, G.; Elena, H.; Willisch, P.; Martinez, M.; Leyba, R.; Triñanes, A.; Medina, M.; Fernandez, I.; Casal, J.; Muñoz, V.

Book ID: 123196536
Publisher: Wielkopolskie Centrum Onkologii
Year: 2013
Tongue: Polish
Weight: 56 KB
Volume: 18
Category: Article
ISSN: 1507-1367
DOI: 10.1016/j.rpor.2013.03.243

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

161 poster Preoperative concurrent radio

161 poster Preoperative concurrent radiotherapy and chemotherapy in uterine cervix cancer

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Radiotherapy with and without cisplatin

Radiotherapy with and without cisplatin in bladder cancer

✍ R. Sauer; J. Dunst M.D.; A. Altendorf-Hofmann; H. Fischer; C. Bornhof; K.M. Schr 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 614 KB

Systemic chemotherapy with high dose con

Systemic chemotherapy with high dose conformal radiotherapy in high risk prostate cancer

✍ A.A Elsaid; S Elassal 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 18 KB

A phase I study of concurrent cisplatin

A phase I study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy

✍ C. NYONGESA; P. RUFF; B. DONDE; J. KOTZEN 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Radiotherapy and Cervix Cancer — Univers

Radiotherapy and Cervix Cancer — University Hospitals Birmingham Experience with Patients Not Suitable for Concurrent Chemoradiotherapy with Cisplatin

✍ E. Beaumont; I.N. Fernando 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Combination chemotherapy with cisplatin

Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer

✍ F. Figoli; A. Veronesi; M. G. Trovo; D. Errante; M. Della Valentina; V. Zagonel; 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 447 KB

A total of 52 consecutive, previously untreated patients with small-cell lung cancer (SCLC) were scheduled to receive six cycles of a combination of etoposide (75 mg/m2 per day) and cisplatin (20 mg/m2 per day), each cycle given over 5 consecutive days. In all, 28 patients had extensive disease (ED)